Abstract: An increase in the availability of emergency contraception (EC) may lead to a decrease in the abortion rate. The 2006 FDA ruling, which relaxed the prescription requirement for EC for women 18 and older, allows us to apply the difference-in-difference methodology on the age-by-year-by-state abortion data to test this hypothesis. Contrary to the literature, we find a moderate reduction in abortion rates among women aged 18 and 19 after 2006 in states that were affected by the change, compared to changes in the control group. These results are robust in a number of specifications and pass the event specification test. (J13, J18) † Corresponding author.
I. INTRODUCTION
In June 2013, the Food and Drug Administration (FDA) approved over the counter sales of Plan B One-Step, a single dose emergency contraceptive (EC) for women of all ages. The decision came after more than a decade of controversy and two years after the Health and Human Services director Kathleen Sebelius overruled the FDA decision and prevented Plan B from being sold over the counter across the country.
1 Unplanned pregnancies impose high costs on women. Therefore, easy and timely access to EC can mitigate these costs.
Plan B, a well-known form of EC, has been available by prescription since 1999. It is an effective and relatively cheap way to avoid unintended pregnancy when other forms of birth control fail, or when birth control is not used. In 2006, the FDA lifted the EC prescription requirement for women 18 years of age or older; those 17 and younger, on the other hand, still required a prescription. The need for a prescription is particularly salient since Plan B works best when it is taken as soon as possible after unprotected sex, and any delays in access lower its efficacy rate. A clear age cut off set by the ruling decreases costs associated with sexual behavior for some young women relative to other young women, and can be exploited to identify a differential response to increased EC access across these two groups.
Unlike most related studies that rely on differences across locations, we use a variation in EC availability across age groups to identify a link between changes in access and fertility
behavior measured with abortion rates. The policy set up (i.e., age differentiation) allows us to improve upon the existing literature by utilizing single age by year data on abortions instead of 5-year age group aggregates commonly used in economic studies. There are likely to be cost differences within the aggregated age groups since available resources, housing options, independence level, and overall financial situation varies as one progresses from age 15 to 19.
Over time, the cost differences across groups can be affected by policy changes, such as the prescription elimination in August 2006 that affected only 18 and 19 year old women. If the change in costs is sufficient, we would expect measurable differences in abortion rates in the years after the policy change.
Using a difference-in-difference methodology, where women aged 15, 16, and 17 are treated as a control group, and focusing on states that were affected by the FDA policy change, we find a considerable reduction in abortion rates among women aged 18-19 in the years following the FDA's announcement in 2006, compared to changes in the control group. The relative magnitude of change associated with the elimination of the prescription requirement ranges from 8-9% (or 1.6-1.8 abortions per 1,000 women). However, the magnitude, to some extent, is driven by a substantially large change in abortion rates among "treated" women in 2010. The exclusion of 2010 yields a more conservative estimate of 6%, or 1.2-1.3 abortions.
We do not observe a similarly large reduction in abortion rates in the post-policy years among women aged 20-24. After adjusting for a small number of clusters, we also fail to reject the null of zero effect for this age group. Further disaggregation of women aged 18-19 into two separate age groups indicates that the effect might be concentrated among women aged 18. The magnitude of the effect, to some degree, is sensitive to the choice of the control group (age 15 or 16), and the use of population weights. All estimated models pass the event-study specification test. Our estimation strategy also passes the falsification test.
The results reported here are in contrast to Gross et al (2013) , who conclude that the change in the FDA's policy does not affect abortion rates among women under the age of 20.
Differences in results might be due to differences in empirical strategies. We use across age variation in cost differences for young women in states that were affected by the change, whereas
Gross et al utilize across state differences in costs, effectively comparing abortion rates in states that were not affected by the FDA announcement (i.e. pharmacy EC access states) and states that were affected by the change. The latter strategy does not take advantage of the cost variation within the 15-19 age group created by the FDA policy.
II. MECHANISMS LINKING ACCESS TO EC AND FERTILITY RATES
There are two competing mechanisms that link access to EC and abortion rates. First, other things being constant, lower costs of EC and/or easier access to EC should increase its use, resulting in fewer unwanted pregnancies and hence lower abortion rates (as unwanted pregnancies are more likely to be terminated). Such a change in unwanted fertility rates is conditional on the assumption that women are aware of the effectiveness of EC and its availability, and actually use it. Research finds that young adults aged 18-24 are aware of EC (Baldwin et al 2008) , can use it correctly (Glasier and Baird 1998) , and that easier access to EC increases its use (Glasier et al 2004 , Raine et al 2000 . The elimination of a prescription requirement makes access to EC easier, and reduces the overall cost of obtaining EC, particularly by lowering the financial cost.
2 However, despite changes in EC use rates due to easier access, there is limited evidence in the literature in favor of a negative relationship between easy EC access and abortion rates. In a study focused on across county variation in access to EC within Washington state, Cintina (2014) finds that increased access to EC is associated with a statistically significantly decrease in the abortion rate among young women in the affected counties. However, the economic effect associated with a presence of no-prescription EC pharmacies is rather small and does not affect abortion rates substantially.
3
An alternative mechanism is that, in response to easier access to EC, young adults may increase sexual risk taking (e.g., sex without contraception) because they know that the cost of unplanned pregnancy has decreased. This scenario is conditional on the assumption that young adults know about the changes in the legislation and take them into account while making decision regarding risky sex. In this case, if women take EC after unprotected intercourse to avoid an unplanned pregnancy, the change in fertility rates associated with changes in sexual behavior should not be substantial. The effect (if any) will be driven by factors associated with the effectiveness and correct usage of the pills (EC is not 100% effective and needs to be taken within a narrow time frame). However, if young adults on average are not forward looking and risky sex occurs on the spur of the moment, then there should not be substantial changes in risk taking.
Research produces mixed results with respect to the link between EC and increase in risky sexual behavior. For example, Girma and Paton (2011) and Durrance (2013) find that increased access to EC increases sexually transmitted disease (STD) rates, which are used as a proxy for risky sexual behavior. Paton (2006) finds that free access to EC at pharmacies is positively associated with sexually transmitted infection (STI) diagnoses, but the statistical power of results varies across models depending on a deflator used for a family planning 2 Marciante et al (2001) find that, depending on the model, the cost savings associated with obtaining EC at a pharmacy without a prescription could vary between $50 for a public payer and $160 for a private payer. 3 Oza (2009) also found a decrease in abortions among 15-29 year-old women due to the FDA's policy change in 2006. However, abortion rates in Oza's dataset are greatly understated, and the claimed 37.2% magnitude reflects the peculiarity of the insurance claims data used in the analysis.
measure, which is also included in the model. In contrast, a number of advanced provision randomized control trial studies do not find evidence of increased risk taking, as measured by sexual activity, use of contraception, and risk of STDs (Gold et al 2004 , Stewart et al 2003 .
Regardless of these mixed findings about behavior change and EC, the literature that relies on geographical variation in EC availability consistently reports that neither abortion, nor birth and pregnancy rates are statistically significantly affected by an increase in EC access (Durrance 2013 , Gross et al 2013 , Girma and Paton 2011 , Paton 2006 , Paton 2002 . Similarly, studies based on small-scale randomized control trials also do not find differences in abortion rates as a result of easy access to EC (Glasier et al 2004 4 To our knowledge, one randomized control trial study (Shaaban et al 2013) finds that the use of EC pills, as a backup plan for the lactation amenorrhea method, decreases the incidence of unplanned pregnancy during breastfeeding. 5 We also consider women aged 25-29, but this age group did not pass the event-specification test, indicating that women aged 15 to 17 are not a good control group for the 25-29 age group. 6 In a few cases, when a single year of data was missing, we used a linear interpolation or, where available, supplemented data with statistics from the state's Vital Statistics Reports.
avoid restrictions that limit the availability of reproductive health services (including abortion)
locally by obtaining an abortion in a state with less rigorous restrictions (e.g., parental involvement laws for minors' abortion). However, since we focus on the federal change that affected all states, rather than changes in state laws, the occurrence data is less of a concern.
Seven states in our dataset allowed women of any age to access EC at pharmacies without a prescription in certain settings prior to August 2006 (pharmacy access states). 7 We exclude pharmacy access states from the DID analysis as they might differ considerably from the non-pharmacy access states. Figure 1 , which shows abortion rates by age group and pharmacy access status, confirms that abortion rates in all age groups are generally higher in states with the relaxed prescription requirement for EC, and, in some cases, trends in the pre-2007 period are substantially different across the two sets of states. Therefore, the exclusion is appropriate.
Since pharmacy access states do not have an age restriction, "border hopping" with respect to EC may affect abortion rates in the neighboring states. However, it is likely that only women who live in close proximity to the state border (and hence are relatively close to a noprescription EC pharmacy) may be willing to do so as the overall cost, which includes driving time, increases with the distance to the closest no-prescription EC pharmacy. Therefore, for a relatively large share of women, it might be faster and more efficient to get a prescription and buy EC locally. There is not strong evidence of border hopping from Idaho and Oregon to Washington, the first state to allow the no-prescription access to EC in 1998 (Cintina 2014) .
Thus, it is unlikely that the overall aggregate state abortion rate will be affected substantially by the mobility factor, and the use of abortion data by occurrence is acceptable.
The average abortion rates for various ages are reported in Table 1 . It appears that abortion rates have decreased in all age groups after 2006, with slightly larger changes among women younger than 18. For example, the abortion rate among women aged 15-17 decreased from 7.7 abortions to 6.2 abortions per 1,000 women, representing a change of nearly 20%. For women aged 18-19 there was a reduction of about 17%, and a substantially smaller change of 10% among women aged 20-24. The question is whether these differences in abortion rates are statistically significant after controlling for state specific time invariant and time variant socioeconomic characteristics.
IV. METHODOLOGY
To identify whether changes can be attributed to a change in the FDA policy, we start with a baseline DID model given by:
where g indexes age groups, s indexes states, and t indexes years 2000 through 2010.
The dependent variable, Y gst , is the abortion rate per 1,000 women in the corresponding age group (g) in a state-year (st). An indicator, AGE1819, separates the control group, women aged 15-17, and the treatment group, women aged 18-19. The variable AFTER indicates the post-FDA ruling time period 2007-2010. 8 The overall effect of the 2006 FDA ruling on abortion rates among relatively older women, compared with the changes in the abortion rate among relatively younger women, is given by  3 . If easier access increases the use of EC and reduces the incidence of unwanted pregnancies, then the abortion rate will decline, implying a negative  3 . If easier access encourages risky sexual behavior and non-use of contraception, leading to a higher rate of unplanned pregnancies, the abortion rate among affected older women may increase, implying a positive  3 . The latter situation would be observed when a higher incidence of unplanned pregnancy is not entirely offset by the increased use of EC.
The vector X gst includes the state unemployment rate among females by age group, real per capita personal income, the maximum Aid to Families with Dependent Children (AFDC) benefit level for a family of three, and an indicator for the enforced parental involvement (PI) laws, notification and/or consent for minors. 9 The latter variable is set to zero for all ages other than 15 to 17, as the laws affects only under-aged teens. If the policy was enforced for only part of a year, then this variable indicates the fraction of the year the policy was in effect.
Additionally, we include a control for border state PI policies, approximated by the number of neighboring states that either have no PI or have enjoined (unenforced) PI laws. The descriptive statistics of the variables included in the model are reported in Table 1 . To analyze the timing of effects, we introduce a set of interaction terms between the treatment indicator and each year dummy ranging from 2007 to 2010 instead of the AGE1819*AFTER term (we also add a full set of year fixed effects instead of a dichotomous measure, AFTER). Then, equation (1) is estimated for an alternative treatment group, women aged 20-24. It is expected that the effect on the 18-19 age group will be larger than on the 20-24 age group as older women are likely to have more resources, be more independent, and less concerned about their parents finding out about a visit to a doctor for an EC prescription. We also test the sensitivity of the results to the inclusion of state-specific linear trends and the use of population weights. 11 Additionally, for both equation (1) and its variation with the dynamic effects, we analyze residuals to identify whether there are age-specific trends that are not captured by these models. Based on the inspection of age-specific residual plots and the regression analysis, where age-specific residuals are regressed on a linear trend, we conclude that in the vast majority of model-specification combinations, the variation in the residuals cannot be explained by a linear trend (results are not reported here, but are available upon request).
The identification of the DID model relies on the assumption that abortion rates for both the treatment and control group have similar trends in the pre-treatment period, implying that in the absence of the treatment the average changes in abortion rates would be similar for both groups. We test the appropriateness of the DID model by estimating an event-study specification that allows for an unrestricted examination of the differences in the rates between the treatment and control groups in the years prior to and after the 2006 FDA ruling. The inclusion of the full set of interaction effects between age and year also allows for a flexible parameterization of the age-specific time trends. If the model is correct, the estimated coefficients for the interaction terms between the treatment dummy and each year in the period 2000-2005 should be small and statistically insignificant, relative to the FDA's ruling year (the omitted year). The event-study specification is given by:
where notation follows equation (1) Similar to the DID model above, seven pharmacy access states were excluded from the sample.
The sensitivity analysis includes the use of an alternative treatment group (women aged 20-24), the inclusion of state-specific linear trends, and population weights. V. RESULTS
A. Baseline DID Model Results
Results for the DID model are reported in Table 2 . Panel A corresponds to equation (1) rather small. The lack of substantial differences in the abortion rates among women aged 20-24 in the post-policy years is not surprising. We expected to observe a relatively smaller effect, compared to women aged 18-19, due to potential differences in behavior as well as the costs of obtaining EC across age groups (with younger women facing higher costs and therefore benefiting more from the change). The results confirm these differences.
B. Event Specification Test Results
As noted earlier, the credibility of our DID models depends on the assumptions regarding the behavior of women in the control and treatment groups. Figure 2 shows estimates for the interaction terms between the treatment group, age 18-19, and year dummies, with the corresponding 95% confidence intervals. 16 The model also includes a set of state-level socioeconomic characteristics, state and year fixed effects, and state-specific linear trends.
Observations are weighted by the state's female population in the respective age group.
The event-study specification confirms the appropriateness of the DID model: the 95% confidence interval is wide, none of the estimates for the period prior to the FDA's policy change are statistically different from zero at the conventional level of significance, and we do not observe a distinct downward trend in the years prior to 2007. Since clustering when the number of clusters is small underestimates standard errors, not finding an effect when clustering at the state level corresponds to a more conservative approach in ruling out a pre-existing trend. We confirm the validity of these results with the bootstrap-t p-values (we fail to reject the null of zero effect at the 10% level of significance for all interaction terms in the pre-2007 period).
Further restricting the control group to women aged 15-16, instead of 15-17, yields qualitatively similar results (albeit with slightly larger point estimates). Similarly, the DID model with an alternative treatment group, women aged 20-24 (Figure 3) , also passes the specification test.
However, for nearly all years, we fail to reject the null of zero effect using the bootstrap-t method (exceptions are 2009 and 2010 where estimates are marginally statistically significant).
Next, we investigate the effects by single year of age. This strategy allows us to more precisely identify the age groups affected by the change in EC availability. Table 3 shows effects separately for women aged 18 and 19 relative to changes in the control group represented by women aged 15 and 16. Results indicate that numerically, the effect is slightly larger for women 16 The point estimates for all specifications of the event-study models are available upon request. 
C. Robustness Checks and Falsification Test Results
Finally, to test the sensitivity of the results to the definition of the control group, we estimate a series of models where the control group is restricted to a single year of age (i.e., separate models for the age 15, age 16, and age 17 control groups). Figure 5 Finally, it can be argued that state level data used for the analyses artificially increases the sample size as the policy measured varies by age and year rather than by state and year. Panel B in Appendix B shows the most conservative set of results from a panel dataset, where the unit of observation is the average abortion rate in a given age-year. Although this set-up substantially reduces the number of observations, it still permits estimation of a basic DID model. These results confirm a statistically significant decrease in the abortion rate among older women relative to women younger than age 18 in the post-policy years.
VI. CONCLUSION
Unintended pregnancy is a substantial public health concern in United States. According to data from the National Survey of Family Growth, nearly half of all pregnancies in 2006 were unintended (Finer and Zolna 2011) . The consequences of unintended pregnancy are especially high for teenagers as childbearing at a young age can lead to an inferior education and fewer earnings in the future. Changes in access to contraception including EC can reduce unintended pregnancies. For a long time, easy and timely access to EC was obstructed by a requirement to have a doctor's prescription. Given that the efficacy rate of EC is inversely related to time passed since unprotected intercourse, the prescription requirement can make EC less effective, thereby increasing the overall cost of obtaining EC. In 2006, the FDA removed the prescription requirement for women older than age 17. The age restriction was placed in part due to concerns about the potential for irresponsible sexual behavior in teenage girls. Given the mixed results reported in the literature on the link between easy access to EC and sexual risk taking, the analysis of consequences of easy access to EC for teenagers is critical.
We use the 2006 change in the FDA policy, which relaxed the prescription requirement for women aged 18 and older, to test whether the incidence of unintended pregnancies changed among the affected population (i.e. women aged 18 and aged 19 in states subject to the FDA policy change) compared to women in the same states for whom costs did not change (i.e.
women 15, 16, and 17). We hypothesize that, in the absence of behavioral changes in sexual risk taking, we should observe a decrease in abortion rates among women aged 18 and aged 19 in the years following 2006 relative to changes in abortion rates among women aged 15, 16, and 17.
Our results suggest that increased access to EC does not promote irresponsible sexual behavior among young women, as we find a moderate decrease in abortion rates among young women for whom the FDA policy change reduced the cost of EC access. Additionally, this research suggests that the 2006 FDA policy, which increased access to EC, had a differentiated effect on young women and that this effect could not be easily identified using aggregated data on abortion rates.
FIGURE 1 Trends in aggregate abortion rates by age group and pharmacy access status
Note: Pharmacy access states are Alaska, Hawaii, Massachusetts, Maine, New Mexico, Vermont, and Washington. California and New Hampshire also had provisions aimed at bypassing the need for a doctor's prescription, but both do not report abortion data. Note: The coefficients shown are for the interaction terms between treatment age group(s) and year dummies (year 2006 is omitted). Dependent variable is the age specific abortion rate per 1,000 women in the corresponding age group. Standard errors are clustered on state. Specification also includes a set of state-level socio-economic characteristics, state and year fixed effects, and state linear trends. Observations are weighted by state's female population in the respective age group. * significant at 5%; + at 10%. The p-values are obtained using the wild cluster bootstrap-t procedure with 1,000 repetitions. Specifications (1) and (2) correspond to equation (1) and (2), respectively. The additional covariates and weights are as described in the note for 
